Arizona PSPRS Trust Makes New Investment in Replimune Group, Inc. (NASDAQ:REPL)

Arizona PSPRS Trust purchased a new position in Replimune Group, Inc. (NASDAQ:REPL) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 76,100 shares of the company’s stock, valued at approximately $834,000. Arizona PSPRS Trust owned 0.11% of Replimune Group as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Millennium Management LLC grew its holdings in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after purchasing an additional 2,656,173 shares during the period. Braidwell LP grew its stake in shares of Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after buying an additional 2,057,460 shares during the last quarter. Baker BROS. Advisors LP increased its position in Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares in the last quarter. Acadian Asset Management LLC raised its stake in Replimune Group by 63.2% during the second quarter. Acadian Asset Management LLC now owns 185,516 shares of the company’s stock valued at $1,668,000 after buying an additional 71,867 shares during the last quarter. Finally, Cubist Systematic Strategies LLC boosted its holdings in Replimune Group by 282.2% in the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after acquiring an additional 53,313 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

Shares of NASDAQ REPL opened at $14.08 on Monday. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The firm has a market capitalization of $963.35 million, a price-to-earnings ratio of -4.62 and a beta of 1.19. The firm has a 50 day moving average of $11.89 and a 200 day moving average of $10.02.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.07. On average, research analysts anticipate that Replimune Group, Inc. will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 8.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. BMO Capital Markets lifted their price target on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Friday, November 22nd. JPMorgan Chase & Co. raised their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $17.00.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.